Ideaya Biosciences Inc. (30J)
XDUS
Real-time Data
06:00 AM
Day's Range
33.9852 wk Range
19.90Overview - 30J - Ideaya Biosciences Inc.
Key Statistics
Valuation
Enterprise Value
-84.91M
P/E (Trailing)
‪-28.14‬
PEG Ratio
‪-0.72‬
Price / Book
‪2.76‬
EV / EBITDA
‪0.54‬
Profitability
Operating Margin
‪-72.84%‬
Return on Assets
‪-10.24%‬
Return on Equity
‪-11.11%‬
Ownership
Shares Outstanding
96.27M
Price stats
50-Day Avg
‪31.43‬
200-Day Avg
‪28.47‬
Peers - 30J - Ideaya Biosciences Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 30JXDUSIdeaya Biosciences Inc.+37.44%52-week change-26.23P/E (Trailing)—Profit Margin
- 4E2XDUSRelmada Therapeutics Inc.+85.50%52-week change-2.59P/E (Trailing)—Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+84.40%52-week change-45.96P/E (Trailing)—Profit Margin
- 42ZXDUSRevolution Medicines Inc.+82.81%52-week change-30.12P/E (Trailing)—Profit Margin
- 87EXDUSDianthus Therapeutics Inc.+78.08%52-week change-22.38P/E (Trailing)—Profit Margin
- 5NRXDUSNanobiotix S.A.+77.27%52-week change—P/E (Trailing)—Profit Margin
- 5NRAXDUSNanobiotix S.A. American Depositary Shares+77.03%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - 30J - Ideaya Biosciences Inc.
About
Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline features IDE196, a protein kinase C inhibitor in Phase 2/3 clinical trials for cancers with GNAQ or GNA11 mutations; IDE397,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
